HinsBet showed identical results compared to the Novo Nordisk‘s products giving local tolerance and absence of pain at the injection site. The inter-patient variability on glycemic control with HinsBet had been statistically lower than that of NovoLog and Actrapid.
Adocia president and CEO Gerard Soula said they think that they have a unique human insulin formulation which could be a best-in-class insulin product, offering type 1 and 2 diabetics a performance on glycemia control as high as insulin analogs but in a more cost-effective way and with less variability.
Following the Phase I trial, Adocia will initiate a phase IIa study on type 1 diabetics to confirm the fast onset of action and the reduction of variability of HinsBet compared to NovoLog and will partner with a company involved in the diabetic field.
HinsBet comprises human insulin and one polymer of the BioChaperone platform patented by Adocia.
The company designed the polymer to form a molecular complex with human insulin to enable acceleration of insulin blood penetration.